← All trials
NCT07103148
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2025
- Primary completion
- Aug 8, 2026
- Completion date
- Mar 4, 2030
- First posted
- Aug 5, 2025
- Last posted
- Oct 28, 2025
- Enrollment
- 2440
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SanofiLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.